Application of the β-expectation tolerance interval to method validation of the M30 and M65 ELISA cell death biomarker assays.
AffiliationPaterson Institute for Cancer Research, University of Manchester, Manchester Cancer Research Centre, Manchester, United Kingdom.
MetadataShow full item record
AbstractMethod validation should focus on demonstrating that an assay is fit for its intended purpose. We have applied the β-expectation tolerance interval - a statistical approach that predicts the accuracy of assay measurements in the future - to the validation of two different cell death biomarker assays, the M30 and M65 ELISAs. A meta-analysis was conducted on a total of 57 different M30 and M65 assays run over a 2 year period. All code utilised in calculations was developed using MATLAB. The optimal fit to the calibration curve for the M30 assay was shown to be a quartic curve which yielded a β-expectation tolerance interval of +20.5% and -23.6% at β=95% over a wide range of QC standards (88-810 U/L). However, such a fit required at least 7 points to avoid problems with over fitting. A linear fit to the M65 calibration curve normally produced a tolerance interval of less than ±20%, however, marked inter-batch variations were evident. Amelioration of batch to batch variations was accomplished by fitting M65 calibration data preferably to a 4-parameter logistic function or a cubic spline. The minimum number of QC replicates and different assays required to produce reliable accuracy profiles was determined. The β-expectation tolerance interval approach has resulted in further optimisation of the M30 and M65 ELISAs as biomarker assays that should translate into greater accuracy in results generated from clinical trials samples.
CitationApplication of the β-expectation tolerance interval to method validation of the M30 and M65 ELISA cell death biomarker assays. 2011, 879 (13-14):887-93 J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.
JournalJournal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
- Utilization of cytokeratin-based biomarkers for pharmacodynamic studies.
- Authors: Linder S, Olofsson MH, Herrmann R, Ulukaya E
- Issue date: 2010 Apr
- Elevated serum levels of M30 and M65 in patients with locally advanced head and neck tumors.
- Authors: Ozturk B, Coskun U, Sancak B, Yaman E, Buyukberber S, Benekli M
- Issue date: 2009 May
- Is there any impact of plasma M30 and M65 levels on progression-free survival of patients with advanced gastric cancer?
- Authors: Bilici A, Ustaalioglu BB, Ercan S, Orcun A, Seker M, Salepci T, Gumus M
- Issue date: 2011 Aug
- Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma.
- Authors: Cummings J, Ranson M, Butt F, Moore D, Dive C
- Issue date: 2007 Nov
- Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP.
- Authors: Cummings J, Ranson M, Lacasse E, Ganganagari JR, St-Jean M, Jayson G, Durkin J, Dive C
- Issue date: 2006 Jul 3